Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).

Singh HS, Dangas GD, Guagliumi G, Yu J, Witzenbichler B, Kornowski R, Grines C, Gersh B, Dudek D, Mehran R, Stone GW.

Am J Cardiol. 2012 Oct 1;110(7):940-7. doi: 10.1016/j.amjcard.2012.05.026. Epub 2012 Jun 28.

PMID:
22748356
2.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

3.

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Akerblom A, James SK, Koutouzis M, Lagerqvist B, Stenestrand U, Svennblad B, Oldgren J.

J Am Coll Cardiol. 2010 Aug 3;56(6):470-5. doi: 10.1016/j.jacc.2009.10.093.

4.

Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.

Bajaj RR, Mohammad A, Hong T, Irfan A, Sharieff W, Bagnall A, Christie JA, Kutryk MJ, Chisholm RJ, Cheema AN.

J Invasive Cardiol. 2010 Aug;22(8):347-52.

5.

Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.

Raveendran G, Ting HH, Best PJ, Holmes DR Jr, Lennon RJ, Singh M, Bell MR, Long KH, Rihal CS.

Mayo Clin Proc. 2007 Feb;82(2):196-202.

PMID:
17290727
6.

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.

Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.

J Invasive Cardiol. 2003 Jun;15(6):319-23.

PMID:
12777670
7.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

8.

Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.

Koutouzis M, Lagerqvist B, Oldgren J, Akerblom A, Wahlin M, Karlsson T, Albertsson P, Matejka G, Grip L.

Clin Cardiol. 2010 Nov;33(11):686-92. doi: 10.1002/clc.20814.

9.

Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.

Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.

JAMA. 2008 Apr 16;299(15):1788-99. doi: 10.1001/jama.299.15.joc80026. Epub 2008 Mar 30.

PMID:
18375998
10.

Switch from abciximab to eptifibatide during percutaneous coronary intervention.

Wahlin M, Albertsson P, Karlsson T, Matejka G, Odell A, Tahmasebiepour F, Wolmeryd C, Grip L.

Int J Cardiol. 2009 May 29;134(3):393-400. doi: 10.1016/j.ijcard.2008.03.008. Epub 2008 Jul 11.

PMID:
18620765
12.

Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.

Midei MG, Coombs VJ, Lowry DR, Drossner MN, Prewitt KC, Wang JC, Loughrey MB, Gottlieb SO.

Cardiology. 2007;107(3):172-7. Epub 2006 Aug 28.

PMID:
16940721
13.

Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.

Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D.

Am Heart J. 2009 Oct;158(4):569-75. doi: 10.1016/j.ahj.2009.08.008.

PMID:
19781416
14.

The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.

Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O'Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).

J Am Coll Cardiol. 2008 Feb 5;51(5):529-35. doi: 10.1016/j.jacc.2007.09.053.

15.

Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, Mehran R.

JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012.

16.
17.

Superior in-hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions.

Deliargyris EN, Upadhya B, Applegate RJ, Kutcher MA, Gandhi SK, Sane DC.

J Invasive Cardiol. 2004 Nov;16(11):611-6.

PMID:
15550727
18.

Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.

Marmur JD, Poludasu S, Lazar J, Cavusoglu E.

Catheter Cardiovasc Interv. 2009 Feb 1;73(2):214-21. doi: 10.1002/ccd.21773.

PMID:
19156882
20.

Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).

Kirtane AJ, Parise H, Mehran R, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW.

Am J Cardiol. 2010 Jul 15;106(2):180-6. doi: 10.1016/j.amjcard.2010.03.015.

PMID:
20599000

Supplemental Content

Support Center